- $1.23m
- -$8.23m
- $0.67m
Vyant Bio Inc reports results for the quarter ended in June - Earnings Summary
Brief: Vyant Bio Reports Second Quarter And First Half 2022 Results
Vyant Bio Inc expected to post a loss of 15 cents a share - Earnings Preview
Vyant Bio Inc expected to post a loss of 15 cents a share - Earnings Preview
Vyant Bio Inc reports results for the quarter ended in March - Earnings Summary
Brief: Vyant Bio Reports First Quarter 2022 Results And Provides Strategic And Business Highlights
Vyant Bio Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Vyant Bio Inc Files For Offering Of Up To 5.8 Million Shares Of Common Stock By The Selling Stockholder - SEC Filing
Brief: Vyant Bio Inc May Issue And Sell Shares Of Up To $20 Mln
U.S. STOCKS ON THE MOVE-Inspirato Inc, PVH Corp, Whirlpool Corp
U.S. STOCKS ON THE MOVE-Nvidia Corp, BioNTech SE, Adagio Therapeutics Inc
Vyant Bio Inc reports results for the quarter ended in December - Earnings Summary
U.S. STOCKS ON THE MOVE-Pearson PLC, BioNTech SE, Robinhood Markets
Brief: Vyant Bio Reports Quarterly Results
Vyant Bio soars on drug discovery deal for Parkinson's disease
Brief: Vyant Bio And Organotherapeutics Announce Strategic Collaboration To Discover Therapeutics To Treat Parkinson's Disease
Brief: Vyant Bio Reports Third Quarter 2021 Results And Provides Strategic Business Updates
Brief: Masori Therapeutics And Vyant Bio, Inc. Announce New Partnership
Brief: Vyant Bio And Cyclica Announce A Strategic Collaboration To Identify Compounds To Treat Cdkl5 Deficiency Disorder